Savara is developing MOLBREEVI, a potential first-in-class therapy for autoimmune pulmonary alveolar proteinosis (aPAP). The company recently submitted a Biologics License Application (BLA) to the U.S. FDA for MOLBREEVI and is preparing a Marketing Authorization Application for Europe by year-end. If the FDA grants Priority Review and approval is received, MOLBREEVI could potentially be approved by the end of the year. To strengthen its balance sheet ahead of potential approval and commercialization, Savara entered a loan and security agreement with Hercules Capital for up to $200 million. The financing includes $30 million funded at signing, repayment of an existing $26.5 million debt facility, and milestone-contingent availability of additional funds. The loan has a five-year maturity with a 36-month interest-only period that can extend to 60 months upon FDA approval; there are no warrants associated with the agreement. Savara Pharmaceuticals is developing innovative drugs for serious and life‑threatening rare respiratory diseases, with a lead program focused on AeroVanc, a dry powder inhaled antibiotic for MRSA lung infection in people with cystic fibrosis. The company is advancing AeroVanc toward a Phase 3 trial and is in the process of selecting research sites. It expects approximately 80 U.S. and Canadian sites to participate and plans to begin enrollment in Q4 2016. Savara intends to use recently raised funds to advance the AeroVanc Phase 3 study and to expand its pipeline with additional drugs for rare respiratory diseases. The company is led by CEO Rob Neville and is based in Austin, TX. Financially, it closed a $20M Series C financing to support these efforts. Savara Pharmaceuticals is developing AeroVanc, a capsule-based dry powder formulation of vancomycin intended as an inhaled, once- or twice-daily treatment for chronic MRSA lung infections in cystic fibrosis patients. AeroVanc has shown strong safety and pharmacokinetic profiles in phase 1 studies and has orphan drug status. The company is preparing a placebo-controlled phase 2a study expected to enroll 80 CF patients with chronic MRSA infections in the U.S. and Canada to test bacterial load reduction and other clinical outcomes. Savara expects data from the upcoming study around this time next year. To support the trial it recently closed the second tranche of a $16 million Series B financing and has previously received funding and grants from multiple public programs. The company went through the Austin Technology Incubator and was founded in 2007. Savara Pharmaceuticals develops inhaled pulmonary therapeutics and is advancing AeroVanc (vancomycin hydrochloride inhalation powder) as a treatment for pulmonary MRSA infection in cystic fibrosis patients. The company is preparing AeroVanc for a Phase IIa clinical efficacy study. Savara recently completed a first closing of a Series B financing to support development activities. The first closing totaled $8.6M and includes new equity, converting bridge funding, and an anticipated Emerging Technology Fund equity conversion. Leadership is headed by CEO Robert Neville. The company is based in Austin, Texas. Savara develops NanoCluster, a nanotechnology-based formulation approach for high-performance inhalation powders that does not require novel excipients or carrier particles. The company has received a patent allowance from the United States Patent and Trademark Office for the NanoCluster technology. Savara says the technology could enable products that are currently difficult or impossible to develop with conventional inhalation powders. It recently closed the second tranche of its Series A financing, taking the round above its targeted $1.4M total. The proceeds will be used to continue development of NanoCluster and to demonstrate its scalability and performance, according to CEO Rob Neville.

Total raised

$245M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Mar 2025